Lana Janes is Chief Operating Officer at Abdera Therapeutics and has more than 20 years of public and private company management and operations experience that spans the full life cycle of therapeutic product development.

Lana is a co-founder of Abdera Therapeutics, having led the incubation and spin-out of the company from adMare Bioinnovations where she was a venture partner. Prior to that, Lana served as chief patent officer of QLT Inc. where, for 12 years, she was responsible for all aspects of global intellectual property and strategic life cycle management for FDA-approved products Visudyne®, Aczone® and Eligard®, as well as numerous preclinical and clinical-stage pharmaceutical products across multiple therapeutic areas. She also served as SVP of Technology Development in her later years at QLT, where she led the R&D organization and oversaw clinical development of the company’s late-stage ophthalmology assets.

Prior to that, Lana worked as a registered Canadian and U.S. patent agent in the Toronto office of Ogilvy Renault LLP (now Norton Rose Fulbright) and at F. Hoffman-La Roche in Basel, Switzerland, where her practice focused on strategic IP protection for numerous therapeutic and medical device franchises.

Lana sits on the boards of Life Sciences British Columbia and the Centre for Probe Development and Commercialization (CPDC) in Ontario.

Lana received her A.B. in chemistry with honors from Harvard University and her Ph.D. with honors in biological organic chemistry from McGill University, where she also conducted her postdoctoral work in the field of antiviral therapeutics.